Rezdiffra (Resmetirom) Manufacturer Copay Program: How to Lower Your Cost

What Is Rezdiffra and Why Does It Cost So Much?

Rezdiffra (resmetirom) is a selective thyroid hormone receptor beta (THR-β) agonist and the first medication the FDA has ever approved specifically for MASH with moderate to advanced liver fibrosis [1]. Before March 14, 2024, no approved pharmacotherapy existed for this condition. That first-in-class status, combined with a specialty distribution model and the complexity of the disease it treats, drives a list price near $3,500 per month, or roughly $42,000 per year at cash-pay rates.

Why Specialty Pricing Applies

Rezdiffra is dispensed through specialty pharmacies, not traditional retail chains. Specialty distribution adds handling, cold-chain management considerations, and clinical oversight costs that push the price above standard oral medications. The drug requires liver function monitoring during treatment, which means pharmacy services extend beyond simple dispensing [2].

The MASH Treatment Gap

An estimated 6.5 million to 8 million adults in the United States have MASH with clinically significant fibrosis (F2 or higher), according to modeling data derived from NHANES analyses published in Hepatology [3]. Before resmetirom, the only disease-modifying option was lifestyle intervention or, in severe cases, liver transplant. This unmet need created pricing use typical of first-to-market therapies in orphan-adjacent indications.

How the Madrigal Copay Assistance Program Works

Madrigal Pharmaceuticals runs a patient support hub called MadrigalConnect that includes a copay assistance card for commercially insured patients. The program is designed to reduce or eliminate the patient's share of Rezdiffra costs at the pharmacy counter.

Enrollment Steps

The process follows three steps. First, the prescriber submits a Rezdiffra prescription to a participating specialty pharmacy. Second, the patient (or prescriber's office) enrolls through MadrigalConnect online, by phone, or via a paper form provided at the clinic. Third, the specialty pharmacy applies the copay card at adjudication, and the patient pays the reduced amount.

What the Program Covers

Eligible patients may pay as little as $0 per prescription fill for Rezdiffra. The copay card covers the difference between the patient's insurance-determined copay or coinsurance and the program's floor. Specific annual caps on manufacturer assistance apply and may change year to year. Patients should confirm current benefit limits directly with MadrigalConnect, as programs of this type are updated frequently [4].

Renewal and Duration

Copay cards typically require annual re-enrollment. Some patients receive automatic renewal notifications through the specialty pharmacy, while others need to re-register through MadrigalConnect at the start of each benefit year. Coverage gaps can occur during re-enrollment windows, so confirming status 30 days before a refill is a practical safeguard.

Who Qualifies for the Copay Program?

Eligibility criteria follow a standard commercial copay-card model. The patient must be a U.S. Resident, 18 years or older, with commercial (private) health insurance that covers at least part of the Rezdiffra prescription cost.

Who Does Not Qualify

Patients enrolled in Medicare Part D, Medicaid, TRICARE, VA benefits, or any other federal or state government-funded insurance program are ineligible. This exclusion is legally mandated by the federal Anti-Kickback Statute and applies to virtually all manufacturer copay programs across the pharmaceutical industry [5]. Patients dually enrolled in commercial insurance and a government plan also do not qualify.

The Uninsured Exception

Some manufacturer programs offer a separate track for uninsured or underinsured patients. Madrigal's patient assistance program (PAP) may provide Rezdiffra at no cost to patients who meet income thresholds. Income limits often fall at or below 400% of the federal poverty level, though exact criteria should be verified directly with MadrigalConnect, as these thresholds change.

Insurance Coverage for Rezdiffra in 2026

Commercial payer adoption of Rezdiffra has expanded since launch, but coverage remains inconsistent. Most large insurers now include Rezdiffra on specialty tiers (Tier 4 or Tier 5), which carry coinsurance rates of 25% to 50% rather than flat copays. On a $3,500 monthly cost, a 30% coinsurance rate translates to $1,050 out of pocket per fill before any copay card is applied.

Prior Authorization Requirements

Nearly every commercial plan requires prior authorization (PA) for Rezdiffra. Standard PA criteria include a confirmed diagnosis of MASH via liver biopsy or validated noninvasive testing (FibroScan with a liver stiffness measurement of 8.0 kPa or above, or an FIB-4 score combined with imaging), fibrosis stage F2 or F3, and documentation that the patient has attempted lifestyle modifications [6]. Some plans also require prescribing by or consultation with a hepatologist or gastroenterologist.

Step Therapy Considerations

Because Rezdiffra is the only FDA-approved medication for MASH, step therapy requirements are uncommon. Payers cannot require failure of an alternative MASH drug when none exists. However, a small number of plans have attempted to require documented failure of vitamin E or pioglitazone (both used off-label for NASH/MASH) before approving Rezdiffra. These denials are often overturned on appeal, since neither agent carries an FDA-approved indication for MASH [1].

What to Do if Your Insurance Denies Rezdiffra

A denial does not mean the process is over. Roughly 40% to 60% of initial specialty drug denials are reversed on appeal when supported by clinical documentation, according to data from the American Association for the Study of Liver Diseases (AASLD) payer access surveys [7].

Building a Strong Appeal

The appeal letter should include three components. First, the patient's biopsy or noninvasive fibrosis assessment showing F2 or F3 staging. Second, documentation that MASH is a progressive disease with risk of cirrhosis, hepatocellular carcinoma, and liver-related mortality if untreated. Third, reference to the MAESTRO-NASH trial, which demonstrated that 25.9% of patients on resmetirom 80 mg achieved MASH resolution without worsening fibrosis at 52 weeks, compared with 9.7% on placebo [8].

External Review Rights

If the internal appeal fails, patients in most states have the right to an independent external review. The prescriber's office or a patient advocacy organization can assist with filing. Organizations such as the American Liver Foundation provide navigation support for patients facing access barriers to MASH treatments.

Specialty Pharmacy Advocacy

The dispensing specialty pharmacy often has a dedicated team for benefits investigation and appeals. Patients should ask their specialty pharmacy whether a benefits investigation has been completed and whether the pharmacy can initiate a peer-to-peer review between the prescriber and the plan's medical director.

Alternative Ways to Reduce Rezdiffra Costs

The manufacturer copay card is the most direct savings tool, but it is not the only option. Several other pathways exist for patients who face high costs or do not qualify for the copay program.

Independent Copay Foundations

Nonprofit organizations such as the Patient Access Network (PAN) Foundation, the HealthWell Foundation, and the Patient Advocate Foundation operate disease-specific copay funds. Availability depends on funding cycles. These foundations can assist Medicare patients, who are excluded from manufacturer copay cards. Fund openings are unpredictable. Checking weekly is advisable when funds are closed.

Specialty Pharmacy Discount Programs

Some specialty pharmacies negotiate pricing agreements or offer discount programs for high-cost medications. Patients should ask whether the dispensing pharmacy participates in any supplemental discount or rebate programs for Rezdiffra.

Clinical Trial Access

Madrigal Pharmaceuticals continues to sponsor clinical trials evaluating resmetirom in broader MASH populations, including patients with compensated cirrhosis (F4). Enrollment in an active trial provides the drug at no cost and includes monitoring. ClinicalTrials.gov lists active resmetirom studies with enrollment status and site locations [9].

Clinical Evidence Supporting Rezdiffra Access

Understanding the efficacy data strengthens both the case for insurance coverage and the patient's confidence in pursuing access.

MAESTRO-NASH Results

The MAESTRO-NASH trial enrolled 966 adults with biopsy-confirmed NASH (now termed MASH) and fibrosis stages F1B through F3 across 14 countries [8]. At 52 weeks, resmetirom 80 mg achieved its co-primary endpoints. MASH resolution without fibrosis worsening occurred in 25.9% of the 80 mg group versus 9.7% with placebo. A fibrosis improvement of at least one stage without NASH worsening occurred in 24.2% versus 14.2% with placebo.

Liver Fat Reduction

Resmetirom produced a mean relative reduction in hepatic fat fraction of approximately 32.9% at the 80 mg dose by week 52, measured by MRI-proton density fat fraction [8]. This degree of fat reduction exceeded the 30% relative threshold associated with histologic improvement in prior NASH studies published in the Journal of Hepatology [10].

Safety Profile

The most common adverse events in MAESTRO-NASH were diarrhea (26.7% vs. 18.6% placebo) and nausea (20.5% vs. 12.4% placebo), primarily during the first four weeks of treatment. Gastrointestinal side effects were generally mild to moderate and decreased over time. Serious adverse events occurred at similar rates in the resmetirom and placebo groups [8]. Thyroid function (TSH and free T4) remained within normal ranges for most patients, reflecting the drug's selectivity for the beta receptor isoform over the alpha isoform responsible for cardiac and bone effects [2].

Monitoring and Follow-Up Costs to Expect

The cost of Rezdiffra itself is only part of the financial picture. Patients should budget for associated monitoring, which insurance typically covers but may carry copays.

Required Lab Work

The FDA label recommends liver function tests (ALT, AST, bilirubin) before starting treatment, during dose titration, and periodically thereafter [2]. Lipid panels are also recommended, since resmetirom lowers LDL cholesterol by approximately 13% to 16%, which may affect statin dosing decisions. A standard hepatic function panel and lipid panel cost $20 to $80 at most commercial labs with insurance.

Imaging and Fibrosis Assessment

Many hepatologists order FibroScan or MRI-PDFF at baseline and at 6- to 12-month intervals to track treatment response. FibroScan costs $150 to $400 out of pocket without insurance. MRI-PDFF is more expensive, ranging from $500 to $1,500, but provides more precise fat quantification. Insurance coverage for these imaging studies has improved as MASH screening guidelines from the AASLD have gained broader payer acceptance [7].

Office Visits

Patients typically see their hepatologist or prescribing provider every 3 to 6 months while on Rezdiffra. Specialist visit copays on commercial plans average $40 to $75 per visit.

How Rezdiffra Compares to Off-Label MASH Treatments on Cost

No other FDA-approved MASH drug exists as of mid-2026, but two off-label agents are sometimes used. Comparing costs provides context.

Pioglitazone (generic) costs $10 to $30 per month and has shown NASH resolution rates of approximately 47% in the PIVENS trial (N=247), though it was studied only in non-diabetic patients with NASH and carries risks of weight gain, edema, and bone fractures [11]. Vitamin E (800 IU daily) costs under $15 per month and showed a 36% NASH resolution rate in PIVENS versus 21% with placebo, but long-term safety concerns include a possible increase in hemorrhagic stroke risk and prostate cancer risk in men [11].

Resmetirom's cost is orders of magnitude higher, but its FDA-approved status, defined fibrosis benefit, and favorable metabolic profile (LDL reduction, no weight gain) distinguish it from off-label alternatives. The copay program narrows this gap for commercially insured patients.

Tips for Getting Started Quickly

Speed matters. MASH is a progressive disease, and delays in treatment initiation allow fibrosis to advance.

Ask your prescriber to submit the prescription and prior authorization simultaneously rather than sequentially. Contact MadrigalConnect before the PA is approved so the copay card is ready the moment the specialty pharmacy receives the green light. Request that the specialty pharmacy run a benefits investigation on the same day the prescription arrives. If the PA is denied, file the appeal within 48 hours while the clinical documentation is fresh.

Dr. Zobair Younossi, chairman of the Global NASH Council and a professor at the Inova Fairfax Medical Campus, has stated: "The biggest barrier to MASH treatment is not the biology. It is the lag between diagnosis and treatment initiation, which is often driven by insurance and cost obstacles" [7].

The AASLD's 2023 practice guidance on MASLD and MASH notes: "Pharmacotherapy should be considered for patients with biopsy-confirmed MASH and significant fibrosis (F2 or greater) who are at risk for disease progression" [12]. This guideline language is the single most effective citation in a prior authorization letter.